- Open
- 72.50
- High
- 75.00
- Low
- 71.25
- Close
- 71.26
- Change
- -2.50 (-3.45%)
- Volume
- 10,065
| 7 Oct 2026 | 16:00:00 | Result of Retail Offer |
| 7 Oct 2026 | 14:35:13 | Holding(s) in Company |
| 30 Sept 2026 | 15:00:00 | Retail Offer to raise up to £130,000 |
| 30 Sept 2026 | 14:58:40 | Results of Placing |
| 11 May 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 13 May 2025 | Annual Report and Accounts (to 2024-12-31) |
Arecor Therapeutics plc is a clinical-stage biotech company developing therapeutics aimed at reducing treatment burden and improving outcomes for individuals with diabetes, obesity, and other cardiometabolic diseases. Its lead product, AT278, is an ultra-concentrated ultra-rapid-acting insulin in development, designed to enhance automated insulin delivery systems. Arecor is also working on a novel oral delivery platform for peptides, targeting GLP-1 receptor agonists as its first validation. The company is based in Cambridge, UK.
| 7 Oct 2026 | 16:00:00 | Result of Retail Offer |
| 7 Oct 2026 | 14:35:13 | Holding(s) in Company |
| 30 Sept 2026 | 15:00:00 | Retail Offer to raise up to £130,000 |
| 30 Sept 2026 | 14:58:40 | Results of Placing |
| 11 May 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 13 May 2025 | Annual Report and Accounts (to 2024-12-31) |
Arecor Therapeutics plc is a clinical-stage biotech company developing therapeutics aimed at reducing treatment burden and improving outcomes for individuals with diabetes, obesity, and other cardiometabolic diseases. Its lead product, AT278, is an ultra-concentrated ultra-rapid-acting insulin in development, designed to enhance automated insulin delivery systems. Arecor is also working on a novel oral delivery platform for peptides, targeting GLP-1 receptor agonists as its first validation. The company is based in Cambridge, UK.
| 30 Sept 2026 |
| 13:29:18 |
| Close of Accelerated Bookbuild to New Orders |
| 13 Aug 2026 |
| Arecor's ultra-concentrated insulin holds ultra-rapid profile in peer-reviewed study - UPDATE |
| 13 Aug 2026 | Arecor's ultra-concentrated insulin holds ultra-rapid profile in peer-reviewed study |
| 12 Aug 2026 | American Resources’ ReElement CTO named recipient of Purdue Engineering 38 by 38 Award |
| 10 Aug 2026 | American Resources CEO joins Trump-hosted mining roundtable in Washington |
| 22 May 2026 | Week Ahead: Kingfisher, Johnson Matthey, SSE, Hollywood Bowl |
| 13 Apr 2026 | Arecor Therapeutics, Great Southern Copper, Powerhouse Energy, Genflow Biosciences, Gelion - Small Cap Snapshot |
| 30 Sept 2026 |
| 13:29:18 |
| Close of Accelerated Bookbuild to New Orders |
| 13 Aug 2026 |
| Arecor's ultra-concentrated insulin holds ultra-rapid profile in peer-reviewed study - UPDATE |
| 13 Aug 2026 | Arecor's ultra-concentrated insulin holds ultra-rapid profile in peer-reviewed study |
| 12 Aug 2026 | American Resources’ ReElement CTO named recipient of Purdue Engineering 38 by 38 Award |
| 10 Aug 2026 | American Resources CEO joins Trump-hosted mining roundtable in Washington |
| 22 May 2026 | Week Ahead: Kingfisher, Johnson Matthey, SSE, Hollywood Bowl |
| 13 Apr 2026 | Arecor Therapeutics, Great Southern Copper, Powerhouse Energy, Genflow Biosciences, Gelion - Small Cap Snapshot |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £42m | -0.2% | |
ARECArecor Therapeutics plc | £27m | -0.1% |
| £12m | +4.0% | |
| £11m | +0.0% | |
| £11m | +0.7% | |
| £9m | -0.7% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £42m | -0.2% | |
ARECArecor Therapeutics plc | £27m | -0.1% |
| £12m | +4.0% | |
| £11m | +0.0% | |
| £11m | +0.7% | |
| £9m | -0.7% |